Stable Cell Lines and Modular Scale-Up Take the Lead

Biotech manufacturing is shifting from transient, one-off production to stable cell lines and modular, transferable scale-up platforms that improve reproducibility, speed tech transfer, and support commercial supply.

• •Stable producer cell lines are replacing transient transfection for more reproducible biologics and gene therapy output.
• •CDMOs are investing in modular, single-use, and continuous systems to make capacity easier to transfer and expand.
• •Commercial readiness now depends on process portability, inspection status, and launch-supply reliability.
• •Capital is favoring de-risked manufacturing assets over speculative greenfield builds.
• •Platform-based scale-up can shorten timelines from clinical translation to commercial production.